Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept

Key Points

• The study aims to identify factors that influence inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.
• Analysis of clinical trial data from two studies (CLIPPER, CLIPPER2)
• Focus on demographics and clinical characteristics of participants
• Assessment of treatment outcomes with etanercept
• Several predictors of remission and inactive disease were identified among participants.
• Participants who responded well to etanercept showed higher rates of remission.
• Data suggest that early treatment may improve outcomes.